Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Sanofi

Vertex Pharmaceuticals

Analysts expect one of them could skyrocket more than 40% over the next 12 months.

3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30%

Bristol Myers Squibb (BMY) closed at $59.84 in the latest trading session, marking a -0.65% move from the prior day.

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

Acceleron Pharma

Bristol-Myers Squibb Co. ( BMY , Financial) is the odds-on favorite to acquire Acceleron Pharma Inc. ( XLRN , Financial) and the rights to its two promising drugs, reported Bloomberg.

Bristol-Myers Reportedly Most Likely Buyer of Acceleron Pharma

Air Products and Chemicals

Comcast

Cisco Systems

General Dynamics

Illinois Tool Works

JPMorgan Chase & Co

Mastercard

Main Street Capital

Nucor

Realty Income Corp

Stryker

Toronto-Dominion Bank

Verizon

W. P. Carey

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: September 28-October 11, 2021

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--U.S. FDA Accepts BMS's Applications for Opdivo + Yervoy and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal....

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Western Digital

You don't need a mountain of cash to build wealth on Wall Street.

3 No-Brainer Stocks to Invest $200 In Right Now

Agilent Technologies

Accenture Plc

Automatic Data Processing

Federal Agricultural

Albemarle

Allstate

Andersons

Algonquin Power & Utilities

Alexandria Real Estate Equities

Artesian Resources

Atrion

Broadcom

Axis Capital

Brookfield Asset Management

BancFirst

Becton, Dickinson and Co.

Franklin Resources

Brookfield Renewable Partners

Brookfield Infrastructure Partners L.P.

Bank of South Carolina

Cardinal Health

C&F Financial

C.H. Robinson Worldwide

A weekly summary of dividend activity for Dividend Champions and Contenders.

Dividend Champion And Contender Highlights: Week Of September 26

Salesforce

Home Depot

Market sell-offs are perfectly normal and an opportune time to invest in great companies at a discount.

5 Brand-Name Stocks to Buy Hand Over Fist if the Market Is Tumbling

Ironwood Pharma

Nu Skin Enterprises

The Baby Boomers are getting older, which means investors should consider adding undervalued healthcare stocks to their portfolio. The post 3 Cheap Healthcare Stocks to Buy Right Now appeared first on InvestorPlace.

3 Cheap Healthcare Stocks to Buy Right Now

Bristol Myers (BMY) application for fixed-dose combination of LAG-3-blocking antibody relatlimab and immuno- oncology Opdivo gets priority review in the United States.

Bristol Myers (BMY) Opdivo-Relatlimab Combo Gets Priority Review

Bristol Myers Squibb (BMY) closed at $60.50 in the latest trading session, marking a -1.32% move from the prior day.

Bristol Myers Squibb (BMY) Stock Moves -1.32%: What You Should Know

Johnson & Johnson

Eli Lilly

Merck

Pfizer

Drug stocks are in a tailspin, and you need to look no farther than Washington for the primary reason. A White House plan to cut the price of medications has led to a more than 10% drop in the Dow Jones U.S. Pharmaceuticals Index over the past month as investors bailed on Big Pharma, concerned that any price controls would eat into sales and profits.

Big Pharma Stocks Hit Hard by Drug Price Proposals

Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gets positive CHMP recommendation by the EMA for treating adults with gastric cancer, among others.

Bristol Myers' (BMY) Opdivo Combo for Gastric Cancer Gets CHMP Nod

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BLA--U.S. FDA Accepts for Priority Review Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination...

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

Medtronic

Philip Morris

STAG Industrial

STORE Capital

Upcoming Ex-Dividend Dates: September 21-October 4, 2021

Nektar Therapeutics

All signs point to approval of Bempeg, Nektar's flagship anti-cancer compound. Retail investors are still caught in the web of lies propagated by Short & Distort operators.

Nektar And Bristol Myers Squibb Expecting Bempeg Approval

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Opdivo + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal....

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma whose Tumors Express PD-L1 with CPS ≥ 5

Bristol Myers Squibb Co (NYSE: BMY) announced Opdivo (nivolumab) plus Yervoy (ipilimumab) long-term survival data in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC). Data were presented at the European Society for Medical Oncology Virtual Congress 2021 (ESMO21).

Bristol Myers Touts 5-Year Kidney Cancer Data For Opdivo-Yervoy Combo Therapy

Shares of Bristol Myers Squibb Co. BMY, -1.64% slumped 1.7% in midday trading Thursday toward a six-month low, putting them on track to suffer the longest losing streak in 3 1/2 years. The stock is headed for a ninth-straight loss, and has declined 7.8% during that stretch.

Bristol Myers stock falls toward 6-month low, set to suffer longest losing streak in 3 1/2 years

Apple

Costco

Ford Motor Company

Jim Cramer has done an excellent job exciting investors about stocks to buy. That said, let's look at some of his favorite picks.

7 Stocks to Buy to Invest Like Jim Cramer

News for Bristol-Myers Stock (BMY)